
    
      This study is designed to compare 3 years of disease-free survival (DFS) of Icotinib and
      placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.

      Primary Outcome Measure:

      Disease-free survival between Icotinib group and placebo group.

      Secondary Outcome Measures:

      Overall survival between Icotinib group and placebo group. Lung cancer symptoms and
      health-related quality of life (HRQoL) . Number of participants with adverse events.
    
  